Vimarsana
Biggest News Aggregation in the World

Page 3 - Kronos Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kronos Bio Today - Breaking & Trending Today

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Adagene (NASDAQ:ADAG), Aravive (NASDAQ:ARAV) - Vimarsana News

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Adagene (NASDAQ:ADAG), Aravive (NASDAQ:ARAV)

Related Topics:
Kronos BioProcessa Pharma
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board - Vimarsana News

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight - Vimarsana News

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight

/PRNewswire/ -- DelveInsight's Hematopoietic Stem Cell Transplantation Market Insights report includes a comprehensive understanding of current treatment...

Kronos Bio, Inc. (NASDAQ:KRON) COO Barbara Kosacz Sells 10,676 Shares - Vimarsana News

Kronos Bio, Inc. (NASDAQ:KRON) COO Barbara Kosacz Sells 10,676 Shares

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) COO Barbara Kosacz sold 10,676 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $1.18, for a total value of $12,597.68. Following the transaction, the chief operating officer now owns 928,966 shares of the company’s […]

Kronos Bio (NASDAQ:KRON) Given New $2.50 Price Target at HC Wainwright - Vimarsana News

Kronos Bio (NASDAQ:KRON) Given New $2.50 Price Target at HC Wainwright

Kronos Bio (NASDAQ:KRON – Free Report) had its price target cut by HC Wainwright from $9.00 to $2.50 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, Piper Sandler dropped their price objective on Kronos Bio from $7.00 to $6.00 and set an […]